As Biotechnology businesses, ARCA biopharma Inc. (NASDAQ:ABIO) and NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY), are affected by contrast. This especially applies to their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ARCA biopharma Inc.||N/A||0.00||7.93M||-0.82||0.00|
|NovaBay Pharmaceuticals Inc.||15.20M||1.57||4.48M||0.55||2.53|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 demonstrates the return on assets, return on equity and net margins of ARCA biopharma Inc. and NovaBay Pharmaceuticals Inc.
|Net Margins||Return on Equity||Return on Assets|
|ARCA biopharma Inc.||0.00%||0%||0%|
|NovaBay Pharmaceuticals Inc.||-29.47%||-71.9%||-39%|
Risk & Volatility
ARCA biopharma Inc.’s 2.08 beta indicates that its volatility is 108.00% more volatile than that of Standard and Poor’s 500. NovaBay Pharmaceuticals Inc.’s 61.00% more volatile than Standard and Poor’s 500 which is a result of the 1.61 beta.
The Current Ratio and a Quick Ratio of ARCA biopharma Inc. are 8.5 and 8.5. Competitively, NovaBay Pharmaceuticals Inc. has 2.8 and 2.7 for Current and Quick Ratio. ARCA biopharma Inc.’s better ability to pay short and long-term obligations than NovaBay Pharmaceuticals Inc.
Institutional and Insider Ownership
Roughly 15.4% of ARCA biopharma Inc. shares are held by institutional investors while 1% of NovaBay Pharmaceuticals Inc. are owned by institutional investors. 0.89% are ARCA biopharma Inc.’s share held by insiders. Competitively, 25.78% are NovaBay Pharmaceuticals Inc.’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|ARCA biopharma Inc.||5.75%||9.55%||-15.6%||-24.74%||-36.11%||37.93%|
|NovaBay Pharmaceuticals Inc.||-6.67%||-25.69%||12.91%||-17.65%||-59.94%||81.18%|
For the past year ARCA biopharma Inc. was less bullish than NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc. beats on 6 of the 10 factors ARCA biopharma Inc.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.